Warmest congratulations to all authors of the GP-TCM J. Ethnopharmacol. Special Issue, which has now been published! This represents one of the most important milestones of the FP7 GP-TCM Project and we sincerely thank all authors, reviewers and editors (Guest Co-editors Dr. Qihe Xu and Prof. Rudolf Bauer; Editor-in-Chief Prof. Rob Verpoorte) for their hard work and excellent collaboration.

As these publications are supported by public funding from the European Commission (FP7 grant agreement No. 223154), which particularly emphasises the importance of using public funding for public good, the Consortium has made all the articles open access and thus freely available to everyone.

We hope that you will enjoy reading this landmark collection of TCM-related articles as much as we have the pleasure in meeting the challenges. Please feel free to share them with any interested parties. Thank you!


1. Good Practices: The basis for evidence-based medicines.

Verpoorte R.

J Ethnopharmacol. 2012; 140: 455-457


2. Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities.

Uzuner H, Bauer R, Fan TP, Guo DA, Dias A, El-Nezami H, Efferth T, Williamson EM, Heinrich M, Robinson N, Hylands PJ, Hendry BM, Cheng YC, Xu Q.

J Ethnopharmacol. 2012; 140: 458-468


3. Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica.

Chan K, Shaw D, Simmonds MS, Leon CJ, Xu Q, Lu A, Sutherland I, Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P.

J Ethnopharmacol. 2012; 140: 469-475


4. The formation of daodi medicinal materials.

Zhao Z, Guo P, Brand E.

J Ethnopharmacol. 2012; 140: 476-481


5. The potential of metabolic fingerprinting as a tool for the modernisation of TCM preparations.

Sheridan H, Krenn L, Jiang R, Sutherland I, Ignatova S, Marmann A, Liang X, Sendker J.

J Ethnopharmacol. 2012; 140: 482-491


6. Review of current and “omics” methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms.

Ouedraogo M, Baudoux T, Stévigny C, Nortier J, Colet JM, Efferth T, Qu F, Zhou J, Chan K, Shaw D, Pelkonen O, Duez P.

J Ethnopharmacol. 2012; 140: 492-512


7. Pharmacovigilance of herbal medicine.

Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C.

J Ethnopharmacol. 2012; 140: 513-518


8. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: Current status and future perspective.

Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, Chan K, Shaw D, Duez P.

J Ethnopharmacol. 2012; 140: 519-525


9. In-silico studies in Chinese herbal medicines’ research: Evaluation of in-silico methodologies and phytochemical data sources, and a review of research to date.

Barlow DJ, Buriani A, Ehrman T, Bosisio E, Eberini I, Hylands PJ.

J Ethnopharmacol. 2012; 140: 526-534


10. Omic techniques in systems biology approaches to traditional Chinese medicine research: Present and future.

Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazaña J, Hylands PJ.

J Ethnopharmacol. 2012; 140: 535-544


11. MEDLINE-based assessment of animal studies on Chinese herbal medicine.

Tejedor Garcia N, Garcia Bermejo L, Fernandez Martinez AB, Olmos Centenera G, Kumari R, Xu Q, Cheng X, Watson S, Lucio Cazaña FJ.

J Ethnopharmacol. 2012; 140: 545-549


12. Guidelines for randomised controlled trials investigating Chinese herbal medicine.

Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G.

J Ethnopharmacol. 2012; 140: 550-554


13. Comparison of effectiveness and safety between granules and decoction of Chinese herbal medicine: A systematic review of randomized clinical trials.

Luo H, Li Q, Flower A, Lewith G, Liu J.

J Ethnopharmacol. 2012; 140: 555-567


14. Future development of global regulations of Chinese herbal products.

Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, Dou JH, Makarov VG, Pozharitskaya ON, Shikov AN, Kim YS, Huang YT, Chang YS, Jia W, Dias A, Wong VC, Chan K.

J Ethnopharmacol. 2012; 140: 568-586


15. Omics and its potential impact on R&D and regulation of complex herbal products.

Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, Xu Q, Fan TP.

J Ethnopharmacol. 2012; 140: 587-593


16. A review of Omics research in acupuncture: The relevance and future prospects for understanding the nature of meridians and acupoints.

Jia J, Yu Y, Deng JH, Robinson N, Bovey M, Cui YH, Liu HR, Ding W, Wu HG, Wang XM.

J Ethnopharmacol. 2012; 140: 594-603


17. Exploring practice characteristics and research priorities of practitioners of traditional acupuncture in China and the EU-A survey.

Robinson N, Lorenc A, Ding W, Jia J, Bovey M, Wang XM.

J Ethnopharmacol. 2012; 140: 604-613


18. Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy.

Liu SH, Cheng YC.

J Ethnopharmacol. 2012; 140: 614-623


19. Value chains of herbal medicines-Research needs and key challenges in the context of ethnopharmacology.

Booker A, Johnston D, Heinrich M.

J Ethnopharmacol. 2012; 140: 624-633


20. Syndrome differentiation in modern research of traditional Chinese medicine.

Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A, Chan K.

J Ethnopharmacol. 2012; 140: 634-642


Print Friendly, PDF & Email